Genuine purchasing channels and methods of mirikizumab

Mirikizumab is a novel interleukin-23 (IL-23) antagonist currently on the market for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease. The effectiveness and safety of the drug have been verified in multiple clinical trials, but it has not yet been officially launched in the Chinese market. As a result, patients have limited purchasing options in China, and prices have not been clearly announced.

1. Purchase medicine overseas:

Since the original Militizumab drug has not yet been launched in China, patients who need to use the drug usually need to purchase it through overseas channels. The common strength of militizumab is300mg/15mL, which is usually provided as an injection. Purchasing channels include foreign drug sales platforms and specialized cross-border drug purchasing websites. However, patients should pay special attention to choosing formal channels to ensure the quality and legality of drugs.

2. Doctor’s prescription and hospital:

In some countries, militizumab may be already on the market and available by prescription. Patients can purchase and receive treatment through regular hospitals or clinics in countries where the drug has been approved for marketing (such as the United States, Europe, etc.). In these areas, patients can usually obtain drugs under the guidance of doctors, and hospitals are responsible for drug supply and management.

3. Price prediction of Milizumab:

Since Militizumab is not currently available in China, its specific pricing has not yet been determined. However, based on the prices in overseas markets, the price of Militizumab may be higher. For example, the price of Milizumab in the German market is approximately RMB 10,000 per vial of 300mg/15mL. Prices may fluctuate due to exchange rate fluctuations.

Overall, since Militizumab has not yet been launched in China, patients can only purchase it through overseas channels and have to face higher drug costs. As drugs are promoted in global markets, there may be more purchasing options and pricing information in the future.

Keyword tags: Militizumab, purchase channels, overseas drug purchase, price prediction, drug source, medical insurance

Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf